Ibandronate Sodium (2 brand names, 2 dosage forms, 3 routes)
Available dosage forms: TABLET, INJECTABLE.
Routes of administration: ORAL, INJECTION, INTRAVENOUS.
Brand Names
- BONIVA
- IBANDRONATE SODIUM
Related Health Topics
Contraindications
Ibandronate sodium tablets are contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Warnings and Precautions [5.1] ) Inability to stand or sit upright for at least 60 minutes (see Dosage and Administration [2.2], and Warnings and Precautions [5.1] ) Hypocalcemia (see Warnings and Precautions [5.2] ) Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. Cases of anaphylaxis have been reported. (see Adverse Reactions [6.2] ).
Adverse Reactions
The following clinically significant adverse drug reactions are described elsewhere in the labeling: • Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1)] • Hypocalcemia and Mineral Metabolism [see Warnings and Precautions (5.2)] • Musculoskeletal [see Warnings and Precautions (5.3)] • Jaw Osteonecrosis [see Warnings and Precautions (5.4)] • Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)] • Severe Renal Impairment [see Warnings and Precautions (5.6)]
Mechanism of Action
The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Overdosage
No specific information is available on the treatment of overdosage of ibandronate sodium. However, based on knowledge of this class of compounds, oral overdosage may result in hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, dyspepsia, esophagitis, gastritis, or ulcer. Milk or antacids should be given to bind ibandronate sodium. Due to the risk of esophageal irritation, vomiting should not be induced, and the patient should remain fully upright. Dialysis would not be beneficial.